Cargando…
Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patien...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392412/ https://www.ncbi.nlm.nih.gov/pubmed/30837802 http://dx.doi.org/10.1093/eurheartj/suy035 |
_version_ | 1783398476725354496 |
---|---|
author | Rosano, Giuseppe M C Spoletini, Ilaria Agewall, Stefan |
author_facet | Rosano, Giuseppe M C Spoletini, Ilaria Agewall, Stefan |
author_sort | Rosano, Giuseppe M C |
collection | PubMed |
description | Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patients but can also cause drug-induced hyperkalaemia. New therapeutic options exist to enhance potassium excretion in these patients. To this aim, we reviewed pharmacological properties and available data on patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalaemia. These agents have been shown in randomized trials to significantly reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-aldosterone system inhibitors. Additional research should focus on their long-term effects/safety profiles and drug–drug interactions. |
format | Online Article Text |
id | pubmed-6392412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63924122019-03-05 Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate Rosano, Giuseppe M C Spoletini, Ilaria Agewall, Stefan Eur Heart J Suppl Articles Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patients but can also cause drug-induced hyperkalaemia. New therapeutic options exist to enhance potassium excretion in these patients. To this aim, we reviewed pharmacological properties and available data on patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalaemia. These agents have been shown in randomized trials to significantly reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-aldosterone system inhibitors. Additional research should focus on their long-term effects/safety profiles and drug–drug interactions. Oxford University Press 2019-02 2019-02-26 /pmc/articles/PMC6392412/ /pubmed/30837802 http://dx.doi.org/10.1093/eurheartj/suy035 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2019. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Rosano, Giuseppe M C Spoletini, Ilaria Agewall, Stefan Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
title | Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
title_full | Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
title_fullStr | Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
title_full_unstemmed | Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
title_short | Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
title_sort | pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392412/ https://www.ncbi.nlm.nih.gov/pubmed/30837802 http://dx.doi.org/10.1093/eurheartj/suy035 |
work_keys_str_mv | AT rosanogiuseppemc pharmacologyofnewtreatmentsforhyperkalaemiapatiromerandsodiumzirconiumcyclosilicate AT spoletiniilaria pharmacologyofnewtreatmentsforhyperkalaemiapatiromerandsodiumzirconiumcyclosilicate AT agewallstefan pharmacologyofnewtreatmentsforhyperkalaemiapatiromerandsodiumzirconiumcyclosilicate |